TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05152030

Intervention type: DIAGNOSTIC_TEST
Intervention: Traditional Chinese version of the University of Pennsylvania of Smell Identification Test (UPSIT-TC)
Description: The University of Pennsylvania Smell Identification Test (UPSIT), which was developed at the University of Pennsylvania, is one of the most reliable and the most widely used olfactory test.The test consists of four 10-odorant booklets. Each odorant is embedded in 10 to 50 µm urea-formaldehyde polymer microencapsules fixed in a proprietary binder and positioned on a brown strip which is located at the bottom of each page of the test booklet.4 When the examinee takes the test, each of the 40 odorants is released by scratching the strip with a pencil tip. The released odorant is sniffed and the examinee identifies the odorant by choosing a name from a set of 4 odor descriptors.

Intervention type: DIAGNOSTIC_TEST
Intervention: Traditional Chinese version of the University of Pennsylvania of Smell Identification Test (UPSIT-TC)
Description: The University of Pennsylvania Smell Identification Test (UPSIT), which was developed at the University of Pennsylvania, is one of the most reliable and the most widely used olfactory test.The test consists of four 10-odorant booklets. Each odorant is embedded in 10 to 50 µm urea-formaldehyde polymer microencapsules fixed in a proprietary binder and positioned on a brown strip which is located at the bottom of each page of the test booklet.4 When the examinee takes the test, each of the 40 odorants is released by scratching the strip with a pencil tip. The released odorant is sniffed and the examinee identifies the odorant by choosing a name from a set of 4 odor descriptors.

Intervention type: DIAGNOSTIC_TEST
Intervention: Traditional Chinese version of the University of Pennsylvania of Smell Identification Test (UPSIT-TC)
Description: The University of Pennsylvania Smell Identification Test (UPSIT), which was developed at the University of Pennsylvania, is one of the most reliable and the most widely used olfactory test.The test consists of four 10-odorant booklets. Each odorant is embedded in 10 to 50 µm urea-formaldehyde polymer microencapsules fixed in a proprietary binder and positioned on a brown strip which is located at the bottom of each page of the test booklet.4 When the examinee takes the test, each of the 40 odorants is released by scratching the strip with a pencil tip. The released odorant is sniffed and the examinee identifies the odorant by choosing a name from a set of 4 odor descriptors.
Study: NCT01332903

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C] AZD5069
Description: Single 120 mg oral dose administered on Day 1
Study: NCT03136042

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: saline + physiotherapy maneuvers
Description: sputum induction by hypertonic saline at 3% for seven minutes. And more five minutes under physiotherapists maneuvers
Study: NCT03336905

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical activity program and prevention after cancer
Description: Providing a supervised and non-supervised physical activity program for adolescent and Young adult with cancer and improve awareness on cancer prevention recommendations (second cancer risk, healthy lifestyles...)
Study: NCT01761487

Intervention type: DEVICE
Group type: OTHER
Intervention: Gentamicin and polymyxin E
Study: NCT04649996

Intervention type: PROCEDURE
Intervention: Appendectomy
Description: comparison between operative and conservative treatment

Intervention type: PROCEDURE
Intervention: Appendectomy
Description: comparison between operative and conservative treatment
Study: NCT02613663

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Immediate implants with nanobone graft
Description: Extraction of unrestorable tooth replaced with immediate implant and use nanobone graft to fill the gap.
Study: NCT03394885

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: 1200mg IV q3weeks
Study: NCT03533543

Intervention type: DEVICE
Intervention: CEM
Description: All patients with MI hospitalized in the CCU department of Shanghai Tenth People's Hospital will receive 24-hour cardiac monitoring until discharge.

Intervention type: DEVICE
Intervention: CEM
Description: All patients with MI hospitalized in the CCU department of Shanghai Tenth People's Hospital will receive 24-hour cardiac monitoring until discharge.
Study: NCT02784431

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Contour Neurovascular System placement
Description: Patients who meet the eligibility criteria will have their target aneurysm treated with the Contour Neurovascular System device via standard endovascular procedure.
Study: NCT00873574

Intervention type: BIOLOGICAL
Intervention: Blood samples and buccal swabs
Description: Peripheral blood samples (35 ml) and buccal swabs
Study: NCT02613663

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: immediate implants with autogenous bone graft
Description: Extraction of unrestorable tooth replaced with immediate implant and use autogenous bone graft to fill the gap.
Study: NCT03617718

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycine Buffer
Description: Subjects will be asked to perform an Inhaled Glycine Buffer followed by a series of Pulmonary Function Tests (PFTs) and then a research bronchoscopy will happen at visit 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycine Buffer
Description: Subjects will be asked to perform an Inhaled Glycine Buffer followed by a series of Pulmonary Function Tests (PFTs) and then a research bronchoscopy will happen at visit 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycine Buffer
Description: Subjects will be asked to perform an Inhaled Glycine Buffer followed by a series of Pulmonary Function Tests (PFTs) and then a research bronchoscopy will happen at visit 3.
Study: NCT00593177

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTH (1-34) Gel / Placebo Gel
Description: Topical dosing of gel twice daily for eight weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTH (1-34) Gel / Placebo Gel
Description: Topical dosing of gel twice daily for eight weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PTH (1-34) Gel / Placebo Gel
Description: Topical dosing of gel twice daily for eight weeks.
Study: NCT02015481

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabaletta
Study: NCT02963883

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SVO2 group / control group
Study: NCT02094183

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GLP-1
Description: GLP-1

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: low calorie diet
Description: low calorie diet

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: low calorie diet
Description: low calorie diet
Study: NCT03394885

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: 5-6mg/ML IV q3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 70-80 mg/m2 IV q1 week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 15 mg/kg IV q3 weeks
Study: NCT02963883

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SVO2 group / control group
Study: NCT00396786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Description: Rivaroxaban 5 mg once daily plus placebo enoxaparin syringe

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Description: Rivaroxaban 10 mg once daily plus placebo enoxaparin syringe

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Description: Rivaroxaban 20 mg once daily plus placebo enoxaparin syringe

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Description: Rivaroxaban 30 mg once daily plus placebo enoxaparin syringe

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Description: Rivaroxaban 40 mg once daily plus placebo enoxaparin syringe

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: Enoxaparin 40 mg once daily plus Rivaroxaban placebo tablets
Study: NCT02510469

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib Mesylate Tablets 500 mg qd p.o.
Study: NCT04037891

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rVA576
Description: 19 Patients with moderate to severe AKC. the study includes two parts: Part 1: The first 3 patients selected for the study will be treated with the active drug in open-label.~Part 2: Sixteen patients will be randomised 1:1. between active and placebo and patients allocated to either group will receive the appropriate product throughout the trial.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Part 2: Sixteen patients will be randomised 1:1. between active and placebo and patients allocated to either group will receive the appropriate product throughout the trial.
Study: NCT01279668

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast
Description: 10mg tablets, once per day for 28 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: tablets, once per day for 28 days.
Study: NCT01146548

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: FLUOXETINE
Description: 20mg/d, oral administration for 6 weeks, then 40mg/d for 4 months.
Study: NCT03355768

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romidepsin
Description: Intravenous administration on a 28 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romidepsin
Description: Intravenous administration on a 28 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pralatrexate
Description: Intravenous administration on a 28 day cycle
Study: NCT01378299

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone Cypionate
Description: Testosterone cypionate was administered at 200 mg by intramuscular injection every 2 weeks.~DEPo-Testosterone Injection, for intramuscular injection, contains testosterone cypionate which is the oil-soluble 17 (beta)-cyclopentylpropionate ester of the androgenic hormone testosterone.~Testosterone cypionate is a white or creamy white crystalline powder, odorless or nearly so and stable in air. It is insoluble in water, freely soluble in alcohol, chloroform, dioxane, ether, and soluble in vegetable oils. The chemical name for testosterone cypionate is androst-4-en-3-one,17-(3-cyclopentyl-1oxopropoxy)-, (178)-. Its molecular formula is CvH400a, and the molecular weight of 412.61.
Study: NCT04154657

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conductance catheter measurement
Description: biventricular parallel conductance catheter measurement at rest and stress conditions, + CMR at rest and stress
Study: NCT03284021

Intervention type: DEVICE
Group type: OTHER
Intervention: Fractional erbium-glass 1550 nm laser
Description: The fractional erbium-glass 1550 nm laser will be applied to the previously 100 cm2 determined area of the scalp with the following parameters: 5-10 mm tip, 5-10 mJ, pulse energy 500-1500 MTZ/cm2 density, one to twopasses, static mode.
Study: NCT03182153

Intervention type: DEVICE
Intervention: Extended Cardiac Monitoring
Description: Extended External Cardiac Monitoring
Study: NCT03725293

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Angiodynamics BioFlo Midline Catheter
Description: Placement of Angiodynamics BioFlo Midline Catheter.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Teleflex Arrowg+ard Blue Advanced Midline Catheter
Description: Placement of Teleflex Arrowg+ard Blue Advanced Midline Catheter.
Study: NCT01410162

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: tacrolimus extended release capsules vs Prograf

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: tacrolimus extended release capsules vs Prograf
Study: NCT03638115

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VaSecure™
Description: Drug Coated PTA Balloon Catheter
Study: NCT04510402

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Povidine iodine nasal swabs
Description: Daily versus twice daily nasal application

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Povidine iodine nasal swabs
Description: Daily versus twice daily nasal application
Study: NCT03012282

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Computed Tomography Perfusion Imaging
Description: Undergo CT perfusion sequence
Study: NCT02352532

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dry Needling
Description: The dry-needling treatment will consist of inserting a sterile needle into needling the prone participant's lumbar multifidus and paraspinal muscles, 1-2 times each, in regions of local tenderness to palpation and/or regions with palpable trigger points. All needling treatment will be performed with FDA approved (FDA regulation # 880.5580) disposable 0.30 x 50-60 mm stainless steel Seirin J-type needles (Seirin, Japan). Each needle insertion will last approximately 5 seconds using a pistoning (in and out) technique.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry Needling
Description: The dry-needling treatment will consist of inserting a sterile needle into needling the prone participant's lumbar multifidus and paraspinal muscles, 1-2 times each, in regions of local tenderness to palpation and/or regions with palpable trigger points. All needling treatment will be performed with FDA approved (FDA regulation # 880.5580) disposable 0.30 x 50-60 mm stainless steel Seirin J-type needles (Seirin, Japan). Each needle insertion will last approximately 5 seconds using a pistoning (in and out) technique.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Needling
Description: The sham dry-needling procedure will mimic the dry needling procedures by placing a sharp object in a needling guide tube against the skin (see figure). The sharp object will be rocked and twisted to simulate treatment, but will not pierce the skin. We have used this sham dry-needling technique in a previous study performed at AMEDDC\&S and have found it to be indistinguishable from real dry needling by the great majority of participants.
Study: NCT01225172

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-754807
Description: Tablet, Oral, 100 mg, Daily, Until disease progression or unacceptable toxicity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-754807
Description: Tablet, Oral, 100 mg, Daily, Until disease progression or unacceptable toxicity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: letrozole
Description: Tablets, Oral, 2.5 mg, Daily, Until disease progression or unacceptable toxicity
Study: NCT00537680

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idebenone
Description: Patients ≤ 45 kg/99 lbs: idebenone 450 mg/day; Patients \> 45 kg/99 lbs: idebenone 900 mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idebenone
Description: Patients ≤ 45 kg/99 lbs: idebenone 1350 mg/day; Patients \> 45 kg/99 lbs: idebenone 2250 mg/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was provided as film-coated tablets that were the same size, weight and appearance as the idebenone tablets.
Study: NCT04406012

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: paravertebral block
Description: paravertebral block group
Study: NCT02213549

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ume paste and ginger powder
Study: NCT05317260

Intervention type: DRUG
Intervention: Antiviral Agents
Description: The type of antiviral agents for the individual patient was selected by physicians based on a policy to reimburse a patient's health and comorbidity.

Intervention type: DRUG
Intervention: Antiviral Agents
Description: The type of antiviral agents for the individual patient was selected by physicians based on a policy to reimburse a patient's health and comorbidity.

Intervention type: DRUG
Intervention: Antiviral Agents
Description: The type of antiviral agents for the individual patient was selected by physicians based on a policy to reimburse a patient's health and comorbidity.
Study: NCT05739357

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NIRS, EEG
Description: During the carotic clamp, if cerebral oxygenation decreased for more than 12 % on the operating side from the baseline value, simple interventions as, increasing arterial blood pressure, increasing arterial carbon dioxide tension or increasing oxygen inspiration concentration will be performed.
Study: NCT01901978

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caloric restrictive diet
Description: Patients will meet weekly with a registered dietician.
Study: NCT03983213

Intervention type: PROCEDURE
Intervention: mpfl reconstruction
Description: Harvested gracilis tendon is pulled through patella and femur in anatomic position and locked with interference screw.
Study: NCT02290340

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo intramuscularly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI8897 10 mg
Description: Participants will receive a single dose of MEDI8897 10 milligram (mg) intramuscularly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI8897 25 mg
Description: Participants will receive a single dose of MEDI8897 25 mg intramuscularly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI8897 50 mg
Description: Participants will receive a single dose of MEDI8897 50 mg intramuscularly.
Study: NCT02455388

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High added sugar diet
Description: Controlled feeding study. Participants will be provided with daily coolers containing foods with high (25%) added sugar to consume for 7 consecutive days. Fasting fingerstick blood samples and weight checks will be performed each morning.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High added sugar diet
Description: Controlled feeding study. Participants will be provided with daily coolers containing foods with high (25%) added sugar to consume for 7 consecutive days. Fasting fingerstick blood samples and weight checks will be performed each morning.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low added sugar diet
Description: Controlled feeding study. Participants will be provided with daily coolers containing foods with low (5%) added sugar to consume for 7 consecutive days. Fasting fingerstick blood samples and weight checks will be performed each morning.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low added sugar diet
Description: Controlled feeding study. Participants will be provided with daily coolers containing foods with low (5%) added sugar to consume for 7 consecutive days. Fasting fingerstick blood samples and weight checks will be performed each morning.
Study: NCT03194230

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: With cervical dilatator
Description: Induction of labour by cervical placement of hygroscopic dilators (Dilapan-S Hygroscopic cervical dilator )
Study: NCT02955160

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Multivalent
Description: Pneumococcal conjugate vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Tdap
Description: Tetanus, diphtheria, and pertussis vaccine
Study: NCT02947503

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin TEVA 850 mg
Description: At inclusion, patients (N=500) will be randomized 1:1 to metformin vs usual care (850 mg tablets, 3 times daily or, if tolerance is suboptimal, a lower maximally tolerated dose, 1-2 times daily), on top of diet and lifestyle, with an insulin rescue in both arms if needed.
Study: NCT03245515

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986195
Description: specified dose on specified days
Study: NCT03298074

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib, 500mg,po qd for continuous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide,100mg, PO.QD，D1-D10, Q3W
Study: NCT00625391

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 500 mg medicinal starch pills daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Green Tea Polyphenols (GTP)
Description: 500 mg green tea polyphenols daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo+Tai Chi (TC)
Description: 500 mg medicinal starch daily and Tai Chi (3x/week) for 24 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GTP+TC
Description: 500 mg GTP daily plus TC exercise (3x/week) for 24 weeks
Study: NCT03869567

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cone beam CT
Description: Just after thrombectomy, a cone beam CT will be done, while patient is on angiography table, in order to determine if hemorrhage image is due to contrast accumulation or blood-brain barrier disruption.
Study: NCT01795976

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: NY-ESO-1 T cells

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: cyclophosphamide 60mg/kg/day day -7 and day -6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine given 25mg/m2 day -5 to day -1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Interleukin 2
Description: Interleukin 2 (IL2) immunotherapy given day 0 to day 6
Study: NCT00693446

Intervention type: DRUG
Group type: OTHER
Intervention: Sirolimus
Description: In a first period, the patient will receive Tacrolimus. The time of first administration will be within the first 48H post transplantation. The initial dose will be 0,1 mg/day po. then titrated to maintain trough whole-blood concentrations between 5-15 ng/ml.~In a second period, the patient will receive Sirolimus. The time of first administration of Sirolimus will be between day 60 and day 90 post transplant. Tacrolimus will be stopped at that time.~The initial dose will be 8 mg/day po. till a trough level is obtained and then titrated to maintain trough whole-blood concentrations between 5-15ng/ml.~The dose of sirolimus will be administrated once a day.
Study: NCT03298074

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: Etoposide,100mg, PO.QD，D1-D10, Q3W
Study: NCT00693446

Intervention type: DRUG
Group type: OTHER
Intervention: Tacrolimus
Description: Patients receive Tacrolimus from day 0 to the end of the study. The time of first administration will be within the first 48 hours post transplant.~The dose of tacrolimus will be administrated twice a day. The initial dose will be 0,1 mg/day po. then titrated to maintain trough whole-blood concentrations between 5-15 ng/ml.~Patients receive also rATG , mycophenolate mofetil and corticosteroids.
Study: NCT01754636

Intervention type: OTHER
Intervention: No intervention